文献速递淋巴瘤

晚期霍奇金淋巴瘤的强化治疗策略(HD9与HD12):两项随机试验的长期生存分析

Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
PubMed 文献 · Lancet Haematol · 2018-01-01

对德国霍奇金研究组HD9和HD12两项随机试验进行计划随访分析,评估晚期霍奇金淋巴瘤强化治疗的长期生存。中位观察时间HD9为141个月、HD12为97个月。HD9中eBEACOPP组15年无进展生存和总生存仍显著优于COPP/ABVD组;HD12中4+4方案非劣效于eBEACOPP;残留病灶省略放疗与更差生存相关。

要点

  • HD9中eBEACOPP组15年无进展生存74.0% vs COPP/ABVD组57.0%,HR 0.53。
  • HD9中eBEACOPP组15年总生存80.9% vs COPP/ABVD组72.3%,HR 0.68。
  • HD12中4+4方案10年无进展生存非劣效于eBEACOPP(HR 1.13,非劣效界值1.50)。

核心结论

  • HD9和HD12的长期随访显示,强化一线治疗及对残留病灶的巩固放疗在无进展生存和总生存方面持续获益。
  • 结果支持在晚期霍奇金淋巴瘤中使用eBEACOPP。
  • 由于第二原发恶性肿瘤等晚期毒性影响死亡,需开发毒性更低且同等有效的治疗以进一步改善总生存。

研究设计与样本

  • HD9(1993年2月1日至1998年3月10日)纳入1282例新诊断、组织学证实的晚期霍奇金淋巴瘤患者,随机接受8周期COPP/ABVD交替、8周期bBEACOPP或8周期eBEACOPP。
  • HD12(1999年1月4日至2003年1月13日;ClinicalTrials.gov注册号NCT00265031)纳入1670例新诊断、组织学证实的晚期霍奇金淋巴瘤患者,随机接受8周期eBEACOPP或4周期eBEACOPP+4周期bBEACOPP(4+4),并随机接受初始大肿块和残留病灶巩固放疗或不放疗,分析两个非劣效目标。
  • 两项试验均在GHSG试验协调中心采用最小化法(含随机成分)集中随机,按中心、年龄、分期、国际预后评分、大纵隔肿块有无及巨块病变分层;患者和研究者未设盲;所有分析按意向治疗原则进行。
  • 本随访分析的主要终点为无进展生存(从首次诊断至疾病进展、复发、任何原因死亡或最后疾病状态信息日期删失);关键次要终点包括总生存和第二原发恶性肿瘤发生率。

主要发现

  • HD9中位观察时间141个月(IQR 101-204),HD12为97个月(IQR 69-143)。
  • HD9中15年无进展生存:COPP/ABVD组57.0%(95%CI 50.0-64.0),bBEACOPP组66.8%(95%CI 61.9-71.8),eBEACOPP组74.0%(95%CI 69.0-79.0);15年总生存分别为72.3%(95%CI 66.5-78.1)、74.5%(95%CI 70.1-78.9)、80.9%(95%CI 76.7-85.0)。
  • HD9中eBEACOPP组无进展生存和总生存仍显著优于COPP/ABVD组(HR 0.53,95%CI 0.41-0.69,p<0.0001;HR 0.68,95%CI 0.50-0.93,p=0.015)。
  • HD9中15年第二原发恶性肿瘤累积发生率:COPP/ABVD组7.2%(95%CI 3.7-10.7),bBEACOPP组13.0%(95%CI 9.1-16.9),eBEACOPP组11.4%(95%CI 7.6-15.1)。
  • HD12中4+4方案非劣效于eBEACOPP:10年无进展生存eBEACOPP组82.6%(95%CI 79.6-85.6) vs 4+4组80.6%(95%CI 77.4-83.7),HR 1.13(95%CI 0.89-1.43),在非劣效界值1.50内;10年总生存分别为87.3%(95%CI 84.7-89.9)和86.8%(95%CI 84.2-89.4),HR 1.02(95%CI 0.77-1.36)。

关键数值与推荐

  • HD9中eBEACOPP组15年无进展生存74.0% vs COPP/ABVD组57.0%(HR 0.53,95%CI 0.41-0.69,p<0.0001)。
  • HD9中eBEACOPP组15年总生存80.9% vs COPP/ABVD组72.3%(HR 0.68,95%CI 0.50-0.93,p=0.015)。
  • HD12中4+4方案10年无进展生存80.6% vs eBEACOPP组82.6%(HR 1.13,95%CI 0.89-1.43,非劣效界值1.50)。
  • HD12中有残留病灶患者接受放疗的10年无进展生存89.7% vs 不放疗83.4%(p=0.027);10年总生存94.4% vs 88.4%(p=0.025)。

临床怎么用

  • 作者认为,长期随访结果支持在晚期霍奇金淋巴瘤中使用eBEACOPP。
  • 作者指出,由于第二原发恶性肿瘤等晚期毒性影响死亡,需开发毒性更低且同等有效的治疗以进一步改善总生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although intensified chemotherapy regimens have improved tumour control and survival in advanced-stage Hodgkin's lymphoma, data on the long-term sequelae are scarce. We did preplanned follow-up analyses of the German Hodgkin Study Group (GHSG) trials HD9 and HD12 to assess whether the primary results of these trials-which had shown that intensive initial therapy in advanced-stage Hodgkin's lymphoma has a beneficial effect on treatment outcomes-would continue with longer follow-up. METHODS: In HD9 (Feb 1, 1993, to March 10, 1998), 1282 patients with newly diagnosed, histology-proven, advanced-stage Hodgkin's lymphoma received eight alternating cycles of COPP and ABVD (COPP/ABVD), eight cycles of bBEACOPP, or eight cycles of eBEACOPP. In HD12 (Jan 4, 1999, to Jan 13, 2003; registered with ClinicalTrials.gov [NCT00265031]), 1670 patients with newly diagnosed, histology-proven, advanced-stage Hodgkin's lymphoma received eight cycles of eBEACOPP or four cycles of eBEACOPP plus four cycles of bBEACOPP (4 + 4), plus consolidation radiotherapy to initial bulk and residual disease or no radiotherapy, to analyse two non-inferiority objectives. In both trials, randomisation was done centrally in the GHSG trial coordination centre using the minimisation method including a random component, stratified according to centre, age, stage, international prognostic score, the presence or absence of a large mediastinal mass, and bulky disease. Patients and investigators were not masked to treatment allocation. All analyses were done on the intention-to-treat principle. The primary endpoint of this follow-up analysis was progression-free survival (time from first diagnosis to progressive disease, relapse, or death from any cause or censoring at the date of last information on disease status). To assess whether long-term outcome might be impaired by long-term sequelae, we analysed overall survival and second primary malignant neoplasm incidence as key secondary endpoints. FINDINGS: Median observation time was 141 months (IQR 101-204) in HD9 and 97 months (69-143) in HD12. For HD9 trial patients, 15-year progression-free survival was 57·0% (95% CI 50·0-64·0) for COPP/ABVD, 66·8% (61·9-71·8) for bBEACOPP, and 74·0% (69·0-79·0) for eBEACOPP, 15-year overall survival was 72·3% (95% CI 66·5-78·1), 74·5% (70·1-78·9), and 80·9% (76·7-85·0), respectively. Progression-free survival and overall survival in the eBEACOPP group remained significantly better than in the COPP/ABVD group (hazard ratio [HR] 0·53, 95% CI 0·41-0·69, p<0·0001, and 0·68, 0·50-0·93, p=0·015, respectively). The 15-year cumulative incidence of second primary malignant neoplasms was 7·2% (95% CI 3·7-10·7) after COPP/ABVD, 13·0% (9·1-16·9) after bBEACOPP, and 11·4% (7·6-15·1) after eBEACOPP. For HD12 trial patients, non-inferiority of 4 + 4 was shown, with 10-year progression-free survival of 82·6% (95% CI 79·6-85·6) for eBEACOPP and 80·6% (77·4-83·7) for 4 + 4 (HR 1·13 [0·89-1·43], within non-inferiority margin of 1·50), and 10-year overall survival of 87·3% (95% CI 84·7-89·9) and 86·8% (84·2-89·4), respectively (HR 1·02 [95% CI 0·77-1·36]). Among 555 (37%) patients with residual disease after chemotherapy, omission of radiotherapy was associated with significantly worse 10-year progression-free survival (89·7% [95% CI 85·8-93·6] radiotherapy vs 83·4% [78·2-88·5] for no radiotherapy; p=0·027) and 10-year overall survival (94·4% [91·4-97·3] vs 88·4% [83·8-93·0]; p=0·025). 10-year cumulative second primary malignant neoplasms incidence was 6·4% (95% CI 3·3-9·5) for 4 + 4 and 8·8% (5·2-12·4) for eBEACOPP. INTERPRETATION: Long-term follow-up of HD9 and HD12 shows an ongoing benefit of intensive first-line treatment and consolidation radiotherapy to residual disease in terms of progression-free survival and overall survival. Our results support the use of eBEACOPP in advanced-stage Hodgkin's lymphoma. However, because late toxicities such as second primary malignant neoplasms contribute to mortality, less toxic but equally effective treatments need to be developed to further improve overall survival. FUNDING: Deutsche Krebshilfe e.V.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. von Tresckow B, Kreissl S, Goergen H, et al. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018. PMID: 30290903. doi:10.1016/S2352-3026(18)30140-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。